Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merrimack Pharmaceuticals
• Treatments: Estrogens; Exemestane; Progesterone

Criteria

Inclusion Criteria:

• Locally advanced or metastatic breast cancer

• Histologically or cytologically confirmed ER+ and/or PgR+ and Her2 negative breast cancer

• ≥ 18 years of age

Exclusion Criteria:

• Received prior treatment with exemestane

• Extensive visceral disease (rapidly progressive, life-threatening metastases, including symptomatic lymphangitic metastases)

• Symptomatic CNS disease